Abstract Two novel series of benzimidazole derivatives bearing structural modifications of certain drugs were prepared for evaluation for potential anticancer activity. The first series was a group of alkylating agents, and the second series was a variety of 4-substituted-1- thioacetyl-3-thiosemicarbazides. The tests of some representative products for antileukemic activity against P-388 lymphocytic leukemia indicated no significant effects.
![1-[[2-(1H-benzoimidazol-2-ylsulfanyl)acetyl]amino]-3-(2-methylphenyl)thiourea Structure](https://image.chemsrc.com/caspic/159/62638-89-5.png)